The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells
Open accessAbstract
SUMMARY Glioblastoma multiforme (GBM) displays cellular hierarchies harboring a subpopulation of stem-like cells (GSCs). Enhancer of Zeste Homolog 2 (EZH2), the lysine methyl transferase of Polycomb repressive complex 2, mediates transcriptional repression of pro-differentiation genes in both normal and neoplastic stem cells. An oncogenic role of EZH2 as a transcriptional silencer is well established; however, additional functions of EZH2 are incompletely understood. Here we show that EZH2 binds to and methylates STAT3, leading to enhanced STAT3 activity by increased tyrosine phosphorylation of STAT3. The EZH2-STAT3 interaction preferentially occurs in GSCs relative to non-stem bulk tumor cells, and it requires a specific phosphorylation of EZH2. Inhibition of EZH2 reverses the silencing of Polycomb target genes and diminishes STAT3 activity, suggesting therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 3×
“A recent study reported that STAT3 signaling is a master regulator of mesenchymal transformation of gliomas, and that STAT3 downstream genes are highly expressed in the mesenchymal GBM subtype (Carro et al., 2010; Verhaak et al., 2010).”
BackgroundIdentification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Self-citationGenome-wide maps of chromatin state in pluripotent and lineage-committed cells
Mikkelsen, T. S., Ku, M., Jaffe, D. B., Issac, B., Lieberman, E., Giannoukos, G., Alvarez, P., Brockman, W., Kim, T.-K., Koche, R. P., et al. (2007) · Nature · doi:10.1038/nature06008 · Cited by 4,129
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,662
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
Cancer stem cells in glioblastoma
Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L. L., & Rich, J. N. (2015) · Genes & Development · doi:10.1101/gad.261982.115 · Cited by 1,520
Self-citationKim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471
Targeting STAT3 in Cancer Immunotherapy
Zou, S., Tong, Q., Liu, B., Huang, W., Tian, Y., & Fu, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01258-7 · Cited by 1,050
Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells
Suvà, M. L., Rheinbay, E., Gillespie, S. M., Patel, A. P., Wakimoto, H., Rabkin, S. D., Riggi, N., Chi, A. S., Cahill, D. P., Nahed, B. V., et al. (2014) · Cell · doi:10.1016/j.cell.2014.02.030 · Cited by 944
EZH2: a novel target for cancer treatment
Duan, R., Du, W., & Guo, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00937-8 · Cited by 926
An, Z., Aksoy, O., Zheng, T., Fan, Q.-W., & Weiss, W. A. (2018) · Oncogene · doi:10.1038/s41388-017-0045-7 · Cited by 668
Mechanisms of Jak/STAT Signaling in Immunity and Disease
Villarino, A. V., Kanno, Y., Ferdinand, J. R., & O’Shea, J. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401867 · Cited by 552
Knutson, S. K., Kawano, S., Minoshima, Y., Warholic, N. M., Huang, K.-C., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G., Kumar, N., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0773 · Cited by 523
Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease
DuPage, M., & Bluestone, J. A. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.18 · Cited by 513
Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map
Huynh, J., Chand, A., Gough, D., & Ernst, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0090-8 · Cited by 504
Non-histone protein methylation as a regulator of cellular signalling and function
Biggar, K. K., & Li, S. S.-C. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3915 · Cited by 479
The potential and controversy of targeting STAT family members in cancer
Verhoeven, Y., Tilborghs, S., Jacobs, J., De Waele, J., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X. B., Wouters, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.002 · Cited by 409
Gan, L., Yang, Y., Li, Q., Feng, Y., Liu, T., & Guo, W. (2018) · Biomarker Research · doi:10.1186/s40364-018-0122-2 · Cited by 426
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Singh, N., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 398
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Targeting glioma stem cells through combined BMI1 and EZH2 inhibition
Jin, X., Kim, L. J. Y., Wu, Q., Wallace, L. C., Prager, B. C., Sanvoranart, T., Gimple, R. C., Wang, X., Mack, S. C., Miller, T. E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4415 · Cited by 383
Self-citationCritical roles of non-histone protein lysine methylation in human tumorigenesis
Hamamoto, R., Saloura, V., & Nakamura, Y. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3884 · Cited by 376
Zhang, H., Cai, K., Wang, J., Wang, X., Cheng, K., Shi, F., Jiang, L., Zhang, Y., & Dou, J. (2014) · Stem Cells · doi:10.1002/stem.1795 · Cited by 368
Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells
Schonberg, D. L., Miller, T. E., Wu, Q., Flavahan, W. A., Das, N. K., Hale, J. S., Hubert, C. G., Mack, S. C., Jarrar, A. M., Karl, R. T., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.002 · Cited by 349
Self-citationLi, Z., Hou, P., Fan, D., Dong, M., Ma, M., Li, H., Yao, R., Li, Y., Wang, G., Geng, P., et al. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2016.95 · Cited by 339
The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy
Tolomeo, M., & Cascio, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020603 · Cited by 318
SET for life: biochemical activities and biological functions of SET domain-containing proteins
Herz, H.-M., Garruss, A., & Shilatifard, A. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.09.004 · Cited by 314
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“Trimethylation of K180 by EZH2 enhanced pY-STAT3 in glioblastoma cells, presumably, by blocking access of a tyrosine phosphatase (Kim et al., 2013a).”
BackgroundJak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition
Groner, B., & von Manstein, V. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.05.033 · Cited by 306
Hombach-Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C., Pitz, M., Hamai, A., Siemianowicz, K., Likus, W., Wiechec, E., Toyota, B. D., et al. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.017 · Cited by 292
The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance
Park, S.-Y., Lee, C.-J., Choi, J.-H., Kim, J.-H., Kim, J.-W., Kim, J.-Y., & Nam, J.-S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1405-7 · Cited by 292
Self-citationRegulation and Role of EZH2 in Cancer
Yamaguchi, H., & Hung, M.-C. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.46.3.209 · Cited by 287
Chemical and Biochemical Perspectives of Protein Lysine Methylation
Luo, M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00008 · Cited by 284
Jarid2 Methylation via the PRC2 Complex Regulates H3K27me3 Deposition during Cell Differentiation
Sanulli, S., Justin, N., Teissandier, A., Ancelin, K., Portoso, M., Caron, M., Michaud, A., Lombard, B., da Rocha, S. T., Offer, J., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.020 · Cited by 281
Epigenetics and Trained Immunity
van der Heijden, C. D. C. C., Noz, M. P., Joosten, L. A. B., Netea, M. G., Riksen, N. P., & Keating, S. T. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7310 · Cited by 278
Ito, T., Teo, Y. V., Evans, S. A., Neretti, N., & Sedivy, J. M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.002 · Cited by 265
STAT3, stem cells, cancer stem cells and p63
Galoczova, M., Coates, P., & Vojtesek, B. (2018) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-018-0078-0 · Cited by 269
The complex STATes of astrocyte reactivity: How are they controlled by the JAK-STAT3 pathway?
Ceyzériat, K., Abjean, L., Carrillo-de Sauvage, M.-A., Ben Haim, L., & Escartin, C. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.05.043 · Cited by 185
Huang, S., Wang, Z., Zhou, J., Huang, J., Zhou, L., Luo, J., Wan, Y. Y., Long, H., & Zhu, B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2395 · Cited by 185
Emerging roles for Polycomb proteins in cancer
Pasini, D., & Di Croce, L. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.03.013 · Cited by 133
Mahara, S., Lee, P. L., Feng, M., Tergaonkar, V., Chng, W. J., & Yu, Q. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602079113 · Cited by 87
Zouein, F. A., Altara, R., Chen, Q., Lesnefsky, E. J., Kurdi, M., & Booz, G. W. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00036 · Cited by 82
Lee, S. W., Oh, Y. M., Lu, Y.-L., Kim, W. K., & Yoo, A. S. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.06.007 · Cited by 77
Self-citationNucleus, mitochondrion, or reticulum? STAT3 à La Carte
Avalle, L., & Poli, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092820 · Cited by 74
TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability
Zhou, S., Peng, J., Xiao, L., Zhou, C., Fang, Y., Ou, Q., Qin, J., Liu, M., Pan, Z., & Hou, Z. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03734-4 · Cited by 66
Dasgupta, M., Unal, H., Willard, B., Yang, J., Karnik, S. S., & Stark, G. R. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.603894 · Cited by 64
“STAT3 is methylated on Lys-140 and Lys-180 by the histone methyl transferases SET9 and EZH2, respectively (10, 11).”
BackgroundLima-Fernandes, E., Murison, A., da Silva Medina, T., Wang, Y., Ma, A., Leung, C., Luciani, G. M., Haynes, J., Pollett, A., Zeller, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09309-4 · Cited by 50
A, P., Xu, X., Wang, C., Yang, J., Wang, S., Dai, J., & Ye, L. (2018) · Epigenetics & Chromatin · doi:10.1186/s13072-018-0213-1 · Cited by 30
Epigenetic modification in gliomas: role of the histone methyltransferase EZH2
Bian, E.-B., Li, J., He, X.-J., Zong, G., Jiang, T., Li, J., & Zhao, B. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.941807 · Cited by 12
Metadata
- Authors
- Kim, E., Kim, M., Woo, D.-H., Shin, Y., Shin, J., Chang, N., Oh, Y. T., Kim, H., Rheey, J., Nakano, I., Lee, C., Joo, K. M., Rich, J. N., Nam, D.-H., & Lee, J.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 23
- Issue
- 6
- Pages
- 839-852
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2160689782
- Cited by
- 806
- References
- 75
- FWCI
- 26.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.